Five ETFs Offering Twice The Yield Of 10-Yr Treasuries

By now, arguably all investors know that the yields on U.S. Treasuries, for lack of a better way of putting it, stink. Even when the yield on 10-year Treasuries reached an 11-week high on Oct. 28, that high was just 2.42%. Today, the yield on 10-year Treasuries once again dipped below 2%. Don't bother looking to Europe. Yields on 10-year gilts are barely above 2% while 10-year bunds yield even less than equivalent Treasuries. Try ETFs. In fact, there are over 100 ETFs offering yields that are at least double those offered by 10-year Treasuries. Here are five to consider. JPMorgan Alerian MLP Index ETN AMJ: Alright, so we started with an ETN, not an ETF, but income investors still love MLPs despite the chorus of naysayers saying the asset class is overvalued. AMJ was close to making a new 52-week high before Monday's sour market knocked the ETN lower. Still, AMJ's yield is just under 5%. The combination of a conservative asset class with decent potential for capital appreciation make AMJ a far better than Treasuries. WisdomTree Australia Dividend ETF AUSE: This under-the-radar play goes unnoticed in the conversation about Australia-specific ETFs. However, the WisdomTree Australia Dividend ETF should NOT be ignored when it comes to dividend talk. A yield of almost 6.4% with an emerging markets kicker (AUSE offers enough exposure to Australian companies that are emerging markets plays) make this another ETF to consider over government bonds. PowerShares Senior Loan Portfolio BKLN: An ETF based on institutional leveraged loans may not sound exciting, but the PowerShares Senior Loan Portfolio has proven to be one of 2011's best new ETFs in terms of attracting assets. BKLN made its debut in March and has almost $166 million in assets under management. Even better, the ETF has a distribution yield of 5.77%. iShares MSCI Singapore Index Fund EWS: Probably not the first thought of dividend hunters, but give the iShares MSCI Singapore Index Fund some credit for a dividend yield that's just north of 4%. Plus, if you were waiting for a pullback to get involved with EWS after missing the ETF's October surge, this week may be a blessing for you. With support around $10.30, EWS could find its way back to the $14 area next year. Pharmaceutical HOLDRs PPH: PPH could see a change in composition once it becomes part of the Market Vectors family, but pharmaceutical stocks are prized for their defensive posture and reliable dividends. Among pharma ETFs, PPH is close to the best, if not the best when it comes to yield. Bull Case: Investors will continue to hunt for yield anywhere but with Treasuries. Or a another U.S. debt downgrade triggers a move out of Uncle Sam's debt. Bear Case: Equity markets simply implode leaving wary investors no choice but to embrace government bonds.